Cantor Fitzgerald Predicts OTCMKTS:ZLDPF FY2025 Earnings

Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Zealand Pharma A/S in a report issued on Monday, May 19th. Cantor Fitzgerald analyst P. Agrawal now expects that the company will post earnings of ($4.35) per share for the year, down from their previous estimate of ($4.04). The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.

Separately, William Blair raised Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.

Zealand Pharma A/S Price Performance

ZLDPF stock traded up $0.02 during trading on Thursday, hitting $62.36. The stock had a trading volume of 133 shares, compared to its average volume of 934. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. Zealand Pharma A/S has a twelve month low of $57.97 and a twelve month high of $141.74. The stock has a market capitalization of $4.43 billion, a P/E ratio of -26.42 and a beta of 0.92. The company's 50-day moving average price is $67.25 and its two-hundred day moving average price is $88.65.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The company had revenue of $1.14 million for the quarter, compared to analysts' expectations of $248.61 million.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.